Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03842722
Other study ID # NL64824.058.18
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 13, 2019
Est. completion date September 28, 2023

Study information

Verified date May 2024
Source Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study will describe the change of mitochondrial oxygen tension (mitoPO2) compared to traditional parameters of oxygenation and oxygen balance in the first 24 hours of septic patients admitted to the intensive care unit of an academic hospital. The mitoPO2 will be measured on prespecified measurement moments in the ICU. With each measurement moment, arterial and central venous blood gasses will be taken too.


Description:

Evidence is increasing that there is no clear parameter for tissue oxygenation in critically ill septic patients to guide resuscitation. New studies have shown the potential of protoporphyrin IX-triple state lifetime technique to measure mitochondrial oxygenation tension (mitoPO2) in vivo, which possibly is an early indicator of oxygen disbalance in the cell and therefore a physiological trigger for fluid therapy. Objectives: 1. To describe mitoPO2 measurements in patients with sepsis who are about to receive fluid therapy 2. To describe the effects of fluid therapy and the associated change in mitoPO2 and change in other physiologic measures of tissue oxygenation and oxygen balance 3.To describe the association between mitoPO2 and vital organ (dis)functions and change of SOFA (Sequential organ failure assessment) score after 24hrs 5. To describe the microcirculatory, cellular and mitochondrial function during the first 24 hours of septic patients. Study population: critically ill patients with sepsis which are admitted to the intensive care unit through the emergency department or hospital ward and in whom fluid therapy (crystalloid, albumin and red cell transfusion) is planned. Main study endpoints Primary endpoint: Change in mitoPO2 after fluid therapy. This will be compared to traditional parameters used to measure oxygenation and oxygen balance Secondary endpoints: - Association of mitoPO2 trend with separate (ischemic) organ (dis)function. The SOFA score after 24 hours will also be assessed. - Safety of mitoPO2 measurements in critically ill septic patients. - Description of the association of sepsis with microcirculatory function, cellular function and mitochondrial function. - Description of the association between mitoPO2 change and clinical outcomes , like length of stay(both ICU and in-hospital) and mortality (both ICU and in-hospital).


Recruitment information / eligibility

Status Completed
Enrollment 81
Est. completion date September 28, 2023
Est. primary completion date September 28, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age of patient is at least 18 years - Patients diagnosed with sepsis in the emergency department or hospital ward - Patients are admitted to the ICU via the hospital ward or emergency department - Informed consent is given either by the patient or if the patient is too ill to give informed consent, by his or her legal representative. - Patients have an arterial catheter in situ, since blood samples will be taken for the study. Most patients admitted to the ICU have an arterial catheter in place since it is part of standard care. Exclusion Criteria: - Patients younger than 18 years - Patients with sepsis discharged after emergency department visit - Patients admitted to a hospital ward other than the ICU after emergency department visit - Patients who cannot give informed consent themselves and without a legal representative will be excluded since no informed consent can be obtained - Patients known with porphyria and/or photodermatosis will be excluded, since the risk of phototoxicity - Patients with hypersensitivity to the active substance or to the plaster material of ALA (5-aminolevulinic acid) - Pregnant or breast feeding women since there is no adequate data form the use of ALA in pregnant or breast feeding women - Insufficient comprehensibility of the Dutch language

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Protoporphyrin IX - Triplet State Lifetime Technique
Protoporphyrin IX - Triplet State Lifetime Technique is a way to measure mitochondrial oxygen tension in a non-invasive way at bedside.

Locations

Country Name City State
Netherlands Leiden University Medical Center Leiden

Sponsors (2)

Lead Sponsor Collaborator
Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research Leiden University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of mitoPO2 during first 24 hours of a septic patient The primary endpoint is the change of mitoPO2(mitochondrial oxygenation) before and after fluid therapy in patients with sepsis. This will be compared to traditional parameters used to measure tissue oxygenation and oxygen balance (central venous oxygen saturation, mean arterial pressure and lactate). 24 hours
Secondary SOFA (sequential organ failure assessment) score after 24 hours The association of mitoPO2 change in 24 hours with the Sequential Organ Failure Assessment score after 24 hours will be assessed. With the help of this information, more insight can be given in how much information the cutaneous mitoPO2 measurement gives about the organs separately and together. 24 hours
Secondary Organ (dis)function To describe the association between mitoPO2 change and separate organ functions. 24 hours
Secondary Validation of mitoPO2 measurement with blood based biomarkers of cellular function Cellular function will be assessed with blood-based biomarkers mitochondrial membrane potential (MMP), presence of cellular reactive oxygen species (ROS) molecules and glutathione (GSH) activity. Mitochondrial function will be assessed with mitoPO2 measurements. 24 hours
Secondary Safety (incidence of adverse and serious adverse events) The adverse and serious adverse events of the mitoPO2 measurements will be assessed. 24 hours
Secondary Length of ICU stay Association of mitoPO2 change and length of intensive care unit-stay. 3 months
Secondary Length of hospital stay Association of mitoPO2 change and length of hospital stay. 3 months
Secondary ICU mortality Association of mitoPO2 change and intensive care unit mortality. 3 months
Secondary In-hospital mortality Association of mitoPO2 change and in-hospital mortality. 3 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3